EQUETRO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Equetro, and when can generic versions of Equetro launch?
Equetro is a drug marketed by Validus Pharms and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.
This drug has one patent family member in one country.
The generic ingredient in EQUETRO is carbamazepine. There are twenty-seven drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Equetro
A generic version of EQUETRO was approved as carbamazepine by TARO on October 3rd, 1996.
Summary for EQUETRO
| International Patents: | 1 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 163 |
| Clinical Trials: | 4 |
| Patent Applications: | 4,321 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for EQUETRO |
| What excipients (inactive ingredients) are in EQUETRO? | EQUETRO excipients list |
| DailyMed Link: | EQUETRO at DailyMed |
Recent Clinical Trials for EQUETRO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Validus Pharmaceuticals | Phase 4 |
| Creighton University | Phase 4 |
| Tuscaloosa Research & Education Advancement Corporation | Phase 4 |
Pharmacology for EQUETRO
Anatomical Therapeutic Chemical (ATC) Classes for EQUETRO
Paragraph IV (Patent) Challenges for EQUETRO
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| EQUETRO | Extended-release Capsules | carbamazepine | 100 mg | 021710 | 1 | 2014-05-23 |
| EQUETRO | Extended-release Capsules | carbamazepine | 200 mg and 300 mg | 021710 | 1 | 2007-08-21 |
US Patents and Regulatory Information for EQUETRO
EQUETRO is protected by one US patents.
Patents protecting EQUETRO
Methods for the treatment of bipolar disorder using carbamazepine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Validus Pharms | EQUETRO | carbamazepine | CAPSULE, EXTENDED RELEASE;ORAL | 021710-001 | Dec 10, 2004 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Validus Pharms | EQUETRO | carbamazepine | CAPSULE, EXTENDED RELEASE;ORAL | 021710-002 | Dec 10, 2004 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Validus Pharms | EQUETRO | carbamazepine | CAPSULE, EXTENDED RELEASE;ORAL | 021710-003 | Dec 10, 2004 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EQUETRO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Validus Pharms | EQUETRO | carbamazepine | CAPSULE, EXTENDED RELEASE;ORAL | 021710-002 | Dec 10, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| Validus Pharms | EQUETRO | carbamazepine | CAPSULE, EXTENDED RELEASE;ORAL | 021710-002 | Dec 10, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| Validus Pharms | EQUETRO | carbamazepine | CAPSULE, EXTENDED RELEASE;ORAL | 021710-001 | Dec 10, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| Validus Pharms | EQUETRO | carbamazepine | CAPSULE, EXTENDED RELEASE;ORAL | 021710-003 | Dec 10, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| Validus Pharms | EQUETRO | carbamazepine | CAPSULE, EXTENDED RELEASE;ORAL | 021710-003 | Dec 10, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| Validus Pharms | EQUETRO | carbamazepine | CAPSULE, EXTENDED RELEASE;ORAL | 021710-001 | Dec 10, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EQUETRO
See the table below for patents covering EQUETRO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | H06511484 | ⤷ Try a Trial | |
| European Patent Office | 0660705 | SYSTEME ET METHODE PERFECTIONNES D'ADMINISTRATION DE MEDICAMENTS ET DE TRAITEMENT DES AFFECTIONS PSYCHIATRIQUES, NEUROLOGIQUES ET AUTRES AVEC LA CARBAMAZEPINE (ADVANCED DRUG DELIVERY SYSTEM AND METHOD OF TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISORDERS WITH CARBAMAZEPINE) | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 9301804 | ⤷ Try a Trial | |
| Canada | 2114014 | SYSTEME D'ADMINISTRATION DE MEDICAMENT ET METHODE POUR TRAITER A L'AIDE DE LA CARBAMAZEPINE LES TROUBLES PSYCHIATRIQUES, NEUROLOGIQUES ET AUTRES (ADVANCED DRUG DELIVERY SYSTEM AND METHOD OF TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISORDERS WITH CARBAMAZEPINE) | ⤷ Try a Trial |
| Germany | 69230112 | ⤷ Try a Trial | |
| Greece | 3031448 | ⤷ Try a Trial | |
| Japan | 3806740 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
